Biogen Inc reports results for the quarter ended June 30 - Earnings Summary

Biogen

29/07/2026 14:32

Biogen Inc BIIB.OQ reported quarterly adjusted earnings of $3.60​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $5.47.  The mean expectation of thirty analysts for the quarter was for earnings of $2.95 per share. Wall Street expected results to range from $1.67  to $3.80 per share.
Revenue rose 3.4% to $2.74 billion from a year ago; analysts expected $2.46 billion. 
Biogen Inc's reported EPS for the quarter was 66 cents​.
The company reported quarterly net income of $97.5 million.
Biogen Inc shares had fallen by 4.8% this quarter and gained 16.8% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 15.4% in the last three months.​ 
In the last 30 days, twenty analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 24 "strong buy" or "buy," 12 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Biogen Inc is $225.00, about 8.6% above its last closing price of $205.61
This summary was machine generated from LSEG data July 29 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
2.95
3.60
Beat
Mar. 31 2026 
2.77
3.57
Beat
Dec. 31 2025 
1.61
1.99
Beat
Sep. 30 2025 
3.88
4.81
Beat